IGF1 and cancer: Aside from the specific mechanisms involved, the regulation of PTEN levels by PPARγ agonists, provides a powerful mechanism to shut down the basal or stimulated signals of PI3K cascade and could be exploited for future treatment of cancers in which PTEN is downregulated/lost and IGF-I-mediated signals are amplified.